Sunyer J, Viana M, Alvarez-Pedrerol M, Rivas I, Forns J, Querol X. School air in a traffic city such Barcelona, the BREATHE Study. Presented at the DOHaD 2012 Satellite Meeting; December 6, 2012. Rotterdam, The Netherlands.
Stull DE, Houghton KF, Petrillo J. Rethinking analysis of outcome measures for demonstrating value of pharmaceutical products: implications for study design, personalized medicine, and comparative effectiveness research. Presented at the 2012 ISPOR 15th Annual European Congress; November 2012. Berlin, Germany.
DiCesare J, Garrison L, Oster G, Sacco P. Assessing the reimbursability of new products: a structured approach. Presented at the 2012 ISPOR EUR Workshop; November 2012. Berlin, Germany.
Mansfield CA. Valuing a real (and controversial) proposal through a stated-preference survey. Presented at the Annual Meeting of the Southern Economic Association; November 2012. New Orleans, LA. Previously presented at the Summer Workshop of the Association of Environmental and Resource Economists.
Depro B, Mansfield CA. New evidence of behavioral change and the air quality index. Presented at the Annual Meeting of the Southern Economic Association; November 2012. New Orleans, LA.
Carson R, Baird M, Coon C, Fehnel SE, MacDougall J, Nelson LM. Psychometric evaluation of patient-reported outcome measures assessing IBS-C symptom severity and change: results from two randomized, double-blind, placebo-controlled phase 3 trials of linaclotide. Presented at the ISOQOL 19th Annual Conference; October 1, 2012.
Earnshaw SR. Research in a non-academic setting. Presented at the UNC Fall Seminar in Pharmaceutical Outcomes and Policy; September 26, 2012. Durham, NC.
Zografos L. Considerations for implementing surveys evaluating effectiveness: sample recruitment, ethics, and privacy. Presented at the 28th ICPE International Conference on Pharmacoepidemiology & Therapeutic Risk Management; September 5, 2012. Barcelona.
Williams VSL, Nelson LM, Carson RT, Baird MJ, Coon CD, Fehnel SE, Johnston JM. Factor analyses of patient-reported outcome measures in Irritable Bowel Syndrome with Constipation (IBS-C): results from two randomized, double-blind, placebo-controlled phase 3 trials of linaclotide. Presented at the 2012 ACG Annual Meeting and Postgraduate Course; September 1, 2012. Previously presented at the Joint International Neurogastroenterology and Motility Meeting.
Nelson LM, Williams VS, Carson RT, Baird MJ, Coon CD, Fehnel SE. Factor analyses of chronic constipation patient-reported outcome measures: results from phase 2b and phase 3 trials of linaclotide. Presented at the Joint International Neurogastroenterology and Motility Meeting; September 1, 2012.
Foraster M, Basagana X, Aguilera I, Agis D, Bouso L, Phuleria H, Dratva J, Probst-Hensch N, Schindler C, Kunzli N. Transportation noise (in particular railway noise) and blood pressure in REGICOR compared to SAPALDIA. Presented at the 41st International Congress and Exposition on Noise Control Engineering 2012; August 19, 2012. New York City, NY.
Hartley L, Girling A, Bowater R, Lilford R. Inter-continental differences in the clinical effectiveness of medical interventions: a study using panoramic meta-analysis. Presented at the Department of Health Sciences Seminar at the University of Warwick; June 19, 2012. Coventry, United Kingdom.
Wolowacz SE, Pearson IV, Roskell NS, Shannon PR, Chubb B, Gundgaard J. Development and validation of a cost-utility model for Type 1 diabetes mellitus. Presented at the Mount Hood Six Challenge; June 7, 2012.
Petrillo J, Cano S, McLeod LD, Coon CD. What is the value of classical test theory, item response theory, and Rasch measurement theory in the development of patient-reported outcome instruments? Presented at the 2012 ISPOR 17th Annual International Meeting; June 2012. Washington, DC.
Nelson LM, Stull DE, Coon CD, Gnanasakthy A. Use of latent growth modeling to evaluate construct validity in longitudinal studies. Presented at the 2012 ISPOR 17th Annual International Meeting; June 2012. Washington, DC.
Mansfield CA. Valuing a real (and controversial) proposal through a stated-preference survey. Presented at the Summer Workshop of the Association of Environmental and Resource Economists; June 2012. Asheville, NC.
Brogan AJ, Talbird SE, Thompson J, Miller JD, George S, Hvidsten K. Cost-effectiveness of first-line versus second-line telaprevir combination treatment in the management of chronic hepatitis C virus infection for treatment-naïve patients with IL28B genotype CC. Presented at the 2012 Digestive Disease Week; May 2012.
Harrison CN, Kiladjian J-J, Al-Ali H-K, Gisslinger H, Knoops L, Waltzman RJ, Copley-Merriman K. Health-related quality of life and symptoms in myelofibrosis patients treated with ruxolitinib versus best available therapy. Presented at the European Focus on Myeloproliferative Neoplasms and Myelodysplastic Syndromes; May 2012.
Earnshaw SR. Assessing economic value and application to stroke imaging. Presented at the 50th Annual Meeting and Symposium of the American Society of Neuroradiology; April 2012.
Mladsi D. Linking product attributes with a threshold pricing model: how commercial thresholds can inform the drug discovery process. Presented at the 2012 DIA 24th Annual EuroMeeting; March 2012. Copenhagen, Denmark.
Qin S. Comparing the matching properties of coarsened exact matching, propensity score matching, and genetic matching in a nationwide observational data and a Monte Carlo experiment. Presented at the 35th Annual Conference of Eastern Educational Research Association; February 15, 2012. Hilton Head Island, SC.
Le Moine JG, Launois R. Mixed treatment comparison, cost-effectiveness analysis and budget impact model in the treatment of rheumatoid arthritis after failure of conventional DMARD therapy using comprehensive Bayesian decision analytical modelling. Presented at the 3rd Joint CES/HESG Workshop; January 11, 2012. Aix-en-Provence, France.